HT
REGN icon

Headlands Technologies’s Regeneron Pharmaceuticals REGN Stock Holding History

Headlands Technologies’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,014
Closed -$2.26M – 838
2025
Q3 		$2.26M Sell
4,014
-8,639
-68% -$4.88M 0.18% 126
2025
Q2 		$6.64M Buy
12,653
+9,259
+273% +$5.17M 0.8% 21
2025
Q1 		$2.15M Sell
3,394
-1,997
-37% -$1.37M 0.25% 104
2024
Q4 		$3.84M Sell
5,391
-201
-4% -$169K 0.39% 58
2024
Q3 		$5.88M Buy
+5,592
New +$6.22M 0.68% 28
2024
Q2 		– Sell
-845
Closed -$813K – 1531
2024
Q1 		$813K Sell
845
-398
-32% -$378K 0.2% 130
2023
Q4 		$1.09M Buy
1,243
+1,238
+24,760% +$1.02M 0.33% 71
2023
Q3 		$4.12K Buy
+5
New +$3.93K ﹤0.01% 778
2023
Q1 		– Sell
-3,235
Closed -$2.33M – 716
2022
Q4 		$2.33M Buy
+3,235
New +$2.39M 1.85% 9

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Headlands Technologies's REGN Position: Q4 2025 in Review

Headlands Technologies sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 4,014 shares — an estimated $2.26M sold.

Headlands Technologies first reported a position in REGN in Q4 2022 and held it in 9 quarters. The position peaked at $6.64M in Q2 2025. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Headlands Technologies reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Headlands Technologies sold 4,014 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $2.26M.
  • Headlands Technologies first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 9 quarters.
  • Headlands Technologies's Regeneron Pharmaceuticals position peaked at $6.64M in Q2 2025.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Headlands Technologies's 13F filing for Q4 2025, filed 13 Feb 2026.